Peptide research library · 169 cited guides
For research or laboratory use, you buy online from a research-supply vendor. The material is labeled research use only. No prescription is involved. It ships to every US state. Nobody regulates quality on this route. So the vendor is the only party vouching for the vial. Buy from one that publishes a third-party certificate of analysis for your lot. It should name the lab that signed it.
For clinical use, you go through a licensed prescriber and then a pharmacy. Four peptides have an approved brand behind them. They are semaglutide, tirzepatide, tesamorelin and PT-141. For other approved active ingredients, a 503A compounding pharmacy makes up a dose for one named patient. That route buys sterile fill-finish. It buys endotoxin testing and batch release. And it buys a regulator who can force a recall.
Most searches land on the first path. The compounds people ask about most have no approved product for a prescriber to write. That covers BPC-157, TB-500, epithalon and GHK-Cu. Which channel fits your compound works through all seven, including the ones that are not online.
Ten research-supply vendors, checked on their own storefronts on 13 August 2026. The benchmark compound is BPC-157, priced per milligram so vial sizes compare. The ranking is by what each one publishes, not by what it claims. Disclosure: Where To Buy Peptides earns a commission on purchases made through its links — which is why every cell below is a document you can open or a price you can load yourself.
| Vendor | Publishes a COA | Testing lab | Where the lab is named | BPC-157 $/mg |
|---|---|---|---|---|
| Sports Technology Labs | Third-party, published | MZ Biolabs, Colmaric | On the site and on the report | $11.40 |
| Swiss Chems | Third-party, published | Janoshik | On the site, in the FAQ | $8.00‡ |
| Core Peptides | Third-party, published | Vanguard Laboratory · A2LA 6377.01.01 | Inside the PDF only | $10.40 |
| PS Peptides | Third-party, published | North American Diagnostics | Inside the PDF only | $10.00 |
| BioTech Peptides | Third-party, published | MZ Biolabs | Inside the PDF only | $10.40 |
| American Peptides | Third-party, published, plus a lot lookup | Bioviridian | Inside the PDF only | $12.00 |
| Limitless Biotech | Third-party, on a Google Drive folder | Janoshik | Nowhere — the report is the only trace | Price gated |
| Behemoth Labz | Published, newest about two years old | MZ Biolabs, Colmaric | Inside the PDF only | $12.45 |
| Red Rock Peptides | Claimed, none published | None named | Nowhere | $6.90† |
† Sold in a 10 mg vial only, so the sticker price is not like-for-like against a 5 mg row. ‡ The Swiss Chems listing is the arginine salt, not plain BPC-157, so its row is not strictly like-for-like either; the figure shown is a sale price, and its list price works out at $10.00/mg. Red Rock Peptides is the floor of the set rather than a recommendation: it advertises “Verified With COAs” and publishes none.
Eight of the ten publish a real third-party report. Only three name the testing lab in their own site copy. On the other seven you have to open the PDF and read the letterhead, which is the gap this column exists to show. Price and paperwork move independently: the cheapest row per milligram and the row with no certificate at all sit $0.10/mg apart.
For research use, yes, and no prescription is involved. Research-supply vendors sell them online as research-use-only material, and they ship to every US state. That labeling is the legal basis of the sale, not fine print. The vendor may not market the vial for human use. It may not publish a dose. It may not make a health claim. Buying the vial for lab work is lawful. Buying an unapproved drug for a person is not. That is the same molecule, described a different way. The legal position in full.
There is no official register, so “legit” has to mean something you can check yourself. The strongest check is whether a company publishes a third-party lab report and names the lab in its own site copy. Three of the ten we checked do. Sports Technology Labs names MZ Biolabs and Colmaric. Swiss Chems names Janoshik. Treat any page that names one company without saying what it earns as an advert. This one earns a commission on purchases made through its links.
None, if you mean a shop you can walk into. There is no retail counter for research peptides anywhere in the US. A store selling them over the counter would be marketing them for human use. Three things are genuinely local. A pharmacy fills the four approved peptides on a script. A clinic writes that script. And most pharmacies stock bacteriostatic water. The collagen peptides in a vitamin aisle share a word with this category and nothing else. What is really on sale near you.
Pick the compound first, because the compound decides the channel. For research use: choose a vendor, ask for the lab report on the lot they would ship, compare the price per milligram, and order online. Payment is ordinary. Cards and ACH work at most of the ten. Crypto works at five. One takes Klarna. Shipping is domestic and usually a few days. Free shipping starts between $100 and $300. For clinical use, the purchase starts with a prescriber and not a cart. What is on sale, and at what price.
Guide
Buying guides & basics
Not a ranking — the one email that sorts the market, and the six supplier checks in order of how much signal each carries.
Explainer
Cognitive & neuroactive
Semax has one published human study: 52 healthy adults scanned in 2020. No adverse event table. The side effect list you read online has no source.
Explainer
Weight loss & metabolic
Cagrilintide's side effect record is mostly gastrointestinal, mostly from CagriSema trials, and it stops at 68 weeks. There is no FDA label yet.
Explainer
Cognitive & neuroactive
Marketed DSIP benefits trace to a 1977 rabbit paper, one 1988 cortisol report, and rat stroke work. No human sleep trial confirms the name.
Explainer
Longevity & mitochondrial
5-Amino-1MQ has zero published human trials, so no human side effect record exists. What exists is 11 days of mouse dosing and mechanism theory.
Explainer
Cognitive & neuroactive
Selank's only Western human data is a 2020 fMRI study in 52 healthy adults. Western randomized trials: zero. Here is what was actually measured.
Explainer
Cognitive & neuroactive
The only human before and after for Semax is a 2020 brain scan of 52 healthy adults. No Western randomized trials. Everything else was measured in rat
Retatrutide
Triple GIP/GLP-1/glucagon agonist — the most-searched research peptide in the world, and still investigational.
BPC-157
Pentadecapeptide from gastric juice. The most-cited tissue-repair compound in the field, and the one with the thinnest human evidence.
Tirzepatide
Dual GIP/GLP-1 agonist behind Mounjaro and Zepbound. Approved as a drug; sold separately as a research compound.
NAD+
The redox cofactor at the center of the longevity conversation. Injectable, IV, and oral-precursor routes all behave differently.
KLOW blend
The GLOW trio plus KPV — GHK-Cu, BPC-157, TB-500 and KPV in one 80 mg vial, and no study of any of it together.
GLOW blend
BPC-157 + TB-500 + GHK-Cu in one vial. Three well-studied constituents, zero trials on the combination.
KPV
The C-terminal tripeptide of α-MSH. Anti-inflammatory signal in gut and skin models without the pigmentation effect.
Semaglutide
The GLP-1 analog behind Ozempic and Wegovy — the molecule that started the metabolic-peptide boom.
Ipamorelin
Selective GHS-R agonist — a growth-hormone secretagogue that leaves cortisol and prolactin alone.
MOTS-c
Mitochondrial-derived peptide that activates AMPK. The closest thing the field has to an exercise mimetic.
CJC-1295
GHRH analog. The no-DAC form pulses; the DAC form doesn't — and that difference drives everything else.
Cagrilintide
Long-acting amylin analog. Interesting alone, far more interesting stacked with semaglutide as CagriSema.
GHK-Cu
Copper tripeptide. The best-evidenced cosmetic peptide there is — and injectable and topical are not interchangeable.
Pillar guide
Complete research guide — triple GIP/GLP-1/glucagon agonist: the Phase II readout that reset the upper bound of pharmacological body-weight reduction.
Explainer
Cagrilintide's side effect record is mostly gastrointestinal, mostly from CagriSema trials, and it stops at 68 weeks. There is no FDA label yet.
Trial readout
Cagrilintide + semaglutide fixed-dose combination. 20.4% mean body-weight reduction at 68 weeks — the largest pharmacological figure documented.
Guide
No retail price exists for an unapproved drug. How to normalize research-vial pricing to cost per mg, and why the cheapest sticker rarely is.
Comparison
SURMOUNT-5 head-to-head — tirzepatide outperformed semaglutide on body-weight reduction with comparable adverse-event profile.
Class overview
Six compounds ranked two ways — by trial magnitude and by evidence quality — and why those two orderings disagree.
Mechanism
How a single 39-residue peptide engages two incretin receptors — and why the GIP arm changes the outcome.
FAQ
Indication, dosing schedule, GI tolerability, and where the compounded vs. branded distinction matters.
Pillar guide
The dual agonist that picked glucagon instead of GIP — ~19% in Phase 2, and a liver program that may matter more than the obesity one.
Pillar guide
Complete research guide — FDA-approved dual GIP/GLP-1 agonist: SURMOUNT, SURPASS, and the field-defining body-weight endpoint curves.
Pillar guide
An engineered oxyntomodulin analog approved in China — the most biomimetic design in the class, and the lowest dual-agonist result.
Pillar guide
Pro-apoptotic peptide targeting adipose vasculature. Phase I kidney toxicity halted development — honest safety framing.
Scroll for more →
Pillar guide
Complete research guide — thymosin-β4 (1-43 fragment), actin binding, cell migration, and the cardiac-repair preclinical signal.
Trial readout
36 studies, 35 of them in animals, roughly 80% from one research group. What's claimed, what's behind each claim, and why the mechanism makes the breadth plausible.
Comparison
BPC-157 + TB-500 — the most-named peptide stack in the research community. Where the name came from, the mechanism, and what the evidence supports.
Class overview
The peptides most-studied for joint health, ranked by published evidence — and the standard-of-care context they're usually compared against.
Guide
No human dose-finding trial has ever been run. Why the animal doses do not convert, and why every online chart agrees with every other.
Explainer
Almost every TB-500 benefit traces back to thymosin beta-4 research in animals and cells. Human trials of TB-500 itself number zero.
Mechanism
VEGF-driven angiogenesis (BPC-157) + actin-monomer-driven cell migration (TB-500). Where the mechanisms converge.
FAQ
Reconstitution, half-life, route of administration, and what the literature does and doesn’t say about safety.
Pillar guide
Complete research guide — identity, multifactorial mechanism, the 35:1 preclinical-to-human ratio, FDA Cat 2 / WADA S0 status.
Trial readout
No controlled human safety data exists — three small uncontrolled reports is the entire record. What the animal work shows and what the FDA concluded.
Guide
Research sourcing guide — CAS 137525-51-0, the 503A Category 2 framing, real pricing benchmarks, and the BPC-specific red flags.
Guide
The most-stacked combination in research peptides. What the additive-mechanism case looks like and where it falls apart.
Scroll for more →
Pillar guide
Complete research guide — two molecules share the name: DAC vs. no-DAC half-life, the receptor pharmacology, and the missing human trials.
Trial readout
The honest before-and-after is a blood test, not a photo: IGF-1 restored to the young-adult range in 14 days in 1990s trials — and zero modern RCTs behind the transformation claims.
Comparison
The stabilized FDA-approved GHRH analog vs the discontinued original fragment — mechanism, half-life, evidence depth, regulatory status, and cost, compared honestly.
Explainer
Sermorelin's side effect list comes from a label pulled in 2008, not a trial. The longest controlled dosing study ran 16 weeks. Zero RCTs since 2020.
Guide
The rare compound here with a labeled dose rather than a reconstruction — and two correct numbers that cause most of the confusion.
Class overview
The growth-hormone axis ranked by evidence rather than reputation — and the hypertrophy outcome studies that mostly do not exist.
Mechanism
Growth hormone secretagogue receptor pharmacology — why ipamorelin is more selective than GHRP-2 or hexarelin.
Pillar guide
Complete research guide — the selective ghrelin-receptor agonist: the GH peptide that doesn’t spike cortisol or prolactin.
Pillar guide
GHRH 1-29 analog — the 29-aa original used as Geref through 2008. Mechanism, evidence, and modern half-life context.
Pillar guide
Long R3 IGF-1 with N-terminal extension. Extended half-life, reduced IGFBP binding — honest cancer-biology framing.
Pillar guide
Synthetic GnRH decapeptide. Factrel discontinued; pulsatile-vs-continuous pharmacology, TRT-adjunct off-label.
Pillar guide
GHRP family — high GH-release potency, tachyphylaxis limitation, cardiac-protection preclinical signal.
Scroll for more →
Pillar guide
Complete research guide — Russian tetrapeptide aging program: Khavinson’s 1971 work, the telomerase claims, and the methodological gaps Western labs flagged.
Class overview
A 2025 first-in-class approval for Barth syndrome, genotype-dependent myopathy results, and preclinical aging work — one cardiolipin mechanism throughout.
Explainer
Fat loss, NAD+, muscle, longevity. We trace each 5-Amino-1MQ benefit claim to the study behind it. Most land in mice or cells. Human trials: zero.
Comparison
SS-31 + MOTS-c + NAD+ — three complementary mitochondrial mechanisms. Zero published controlled human trials of the combination.
Mechanism
SIRT1-7 deacetylase dependence on NAD+. The mechanism that anchors most of the popular longevity-market claims for the molecule.
Trial readout
High-fat-fed mouse models show body-weight reduction without locomotor change. Sample size, dose, and translation limits.
Guide
No human trial has established a MOTS-c dose. The exact doses the mouse studies used, why mg/kg does not convert…
Pillar guide
Complete research guide — 16-residue mitochondrial-encoded peptide: the "exercise mimetic" claim, the AMPK story, and the human-trial gap.
Pillar guide
Complete research guide — IV infusion, NMN, NR, NAM: the four ways to address declining cellular NAD+ and what the data actually supports.
Pillar guide
Complete research guide — selective NNMT inhibitor: the murine adipose-tissue signal, the mechanism, and the absent human trials.
Pillar guide
Complete research guide — mitochondria-targeted tetrapeptide, FDA-approved for Barth syndrome (Forzinity, Sept 2025).
Pillar guide
EDR tripeptide, Khavinson school. Russian preclinical work, mitochondrial proposals, thin Western RCT base.
Scroll for more →
Pillar guide
BPC-157 + TB-500 + GHK-Cu in one 70 mg vial. Per-constituent mechanism and evidence — and the honest gap: zero trials on the combined stack.
Guide
Two routes, two evidence bases. Topical has studied concentrations; injectable has zero human RCTs and a copper-load question nobody has looked at.
Explainer
Oral glutathione's side effect record is one 46-person, 8-week trial. The IV route carries FDA warnings citing Stevens-Johnson syndrome and deaths.
Class overview
An honest review of the strongest skin-health peptides, anchored to where the published evidence actually supports each route of administration.
Guide
Pre-mixed 80 mg vial or GLOW plus KPV assembled from two — what each route costs, and the four checks a blend certificate must survive.
Trial readout
A class of trials with positive descriptive findings but persistent methodological holes — and an FDA warning letter on IV use.
Mechanism
Type I/III procollagen mRNA upregulation in dermal fibroblasts. The biochemical case in dermal-aging (photoaging) research.
Comparison
The route-of-administration debate. Why topical formulations dominate the published literature.
Pillar guide
Complete research guide — the master endogenous antioxidant: redox cycling, IV vs. oral controversy, and the skin-lightening evidence base.
Pillar guide
Complete research guide — endogenous copper tripeptide that declines with age, with the strongest topical signal in the catalog.
Pillar guide
Acetyl Hexapeptide-3 — the "Botox-like" SNAP-25 inhibitor. Topical anti-wrinkle evidence and cosmeceutical regulatory framing.
Pillar guide
Palmitoyl Pentapeptide-4 (KTTKS). Topical collagen-stimulating cosmeceutical with dermatology RCT base.
Scroll for more →
Pillar guide
Complete research guide — Russian heptapeptide derived from tuftsin: GABAergic modulation, anti-anxiety claims, and the trial-quality picture.
Class overview
The peptides most-studied for sexual health, ranked by published evidence — and honest about PT-141's 40% nausea rate and Melanotan II's melanoma concerns.
Explainer
The only human before and after for Semax is a 2020 brain scan of 52 healthy adults. No Western randomized trials. Everything else was measured in rat
Comparison
Russian heptapeptide pair — two neuropeptide classes. Institute of Molecular Genetics provenance, honest Western RCT framing.
Mechanism
The ACTH(4-10)Pro-Gly-Pro structure and how it engages BDNF signaling without the corticotropic side-effects of full ACTH.
Trial readout
The pivotal Phase III RECONNECT and PRISM studies — efficacy magnitude, adverse-event profile, and the FDA approval.
Guide
PT-141 is the rare peptide with an approved human dose: 1.75 mg by autoinjector. The label's numbers, its limits…
Pillar guide
Complete research guide — FDA-approved melanocortin agonist for HSDD: Vyleesi, the Phase III data, and the off-label dose-response.
Pillar guide
Complete research guide — the DSIP nonapeptide: 1977 isolation, the sleep-architecture literature, and the trial-quality gap.
Pillar guide
Complete research guide — Russian heptapeptide derived from ACTH(4-10): BDNF upregulation and the stroke-recovery indication.
Class overview
An honest review of the most-marketed sleep peptides, with explicit framing on where the published evidence supports the claims and where it doesn’t.
Explainer
Semax has one published human study: 52 healthy adults scanned in 2020. No adverse event table. The side effect list you read online has no source.
Scroll for more →
Pillar guide
Complete research guide — the C-terminal tripeptide of α-MSH: melanocortin signaling, the cleanest preclinical signal for ulcerative colitis.
Class overview
The peptides most-studied for immune support, ranked by published evidence — including the negative 2025 TESTS Phase III sepsis trial on Thymosin Alpha 1.
Trial readout
An elegant mechanism and the largest gap between marketing and published human evidence of anything in this library.
Guide
No human KPV trial has been published. What the colitis studies administered — 10 nM in culture, 100 µM in mouse…
Mechanism
MC1R-independent anti-inflammatory action. Why a 3-residue peptide retains the parent molecule’s function.
Pillar guide
28-aa Zadaxin/Thymalfasin. 35+ country approval, FDA-unapproved in US. 2025 BMJ TESTS Phase III sepsis negative.
Pillar guide
KEDG tetrapeptide, Khavinson school. Proposed thymic function support; single-source-dominance flagged.
Pillar guide
KE dipeptide, Khavinson cytogen for immune cell proliferation. Honest evidence-base framing.
Class overview
An honest review of the most-cited gut-health peptides, anchored to peer-reviewed preclinical evidence for GI indications.
Guide
Every verified thymosin alpha-1 trial used 1.6 mg subcutaneously — twice weekly for hepatitis, twice daily for…
Trial readout
DSS-induced colitis models, oral and topical formulations, and the dose-response. Human trials still pending.
Class overview
Approved abroad as thymalfasin, unapproved at home, and at the center of FDA's 2026 compounding docket.
Scroll for more →
Pillar guide
Identity before purity, the lab before the number, and the lot match that makes a certificate apply to the vial in your hand.
Guide
What "third-party verified" means in 2026: HPLC purity floor, per-lot third-party COA, mass-spec identity, and the documentation chain that defines the category.
Comparison
HPLC measures purity. LC-MS establishes identity. What each test proves, what a certificate has to report for both, and why one number is not enough.
Explainer
Nothing has been measured for the four-compound blend. Half the vial has no human trial at all, and four fixed variables make attribution impossible.
Class overview
The peptides with the lowest entry barriers for new researchers — ranked by safety, ease of use, and evidence depth.
Pillar guide
Four compounds in one 80 mg vial — GHK-Cu, BPC-157, TB-500 and KPV. What is in it, and what the combination has behind it.
Guide
The published legal position — RUO under 21 CFR §809.10, what “not for human consumption” means, 503A categories, WADA, and buying vs selling vs administering.
Guide
What 'peptides for sale' actually means, why the prices scatter so wildly, and the one request that separates a seller who tests from one who doesn't.
Guide
A 2026 buyer's guide — the eight criteria, real price-per-mg ranges by class, the regulatory framing, and a 30-minute vendor verification checklist.
Guide
The checks that work from outside: the certificate, the named lab, the accreditation lookup, the six questions to ask, and what each red flag means.
Explainer
The 50-amino-acid line that separates a peptide from a protein. Why the distinction matters for half-life, synthesis, and oral bioavailability.
Guide
Frozen vs. refrigerated vs. room-temperature stability windows. Lyophilized vial life, post-reconstitution life, and freeze-thaw cycle limits.
Scroll for more →
Research peptides are sold legally in the United States as research chemicals, labeled research use only and not for human consumption. That labeling is the legal basis for the sale — it is not a formality. Suppliers cannot lawfully market them for human use, make therapeutic claims, or provide dosing instructions. Buying them for laboratory work is legal; a supplier telling you how to inject one is a sign that supplier is not operating within the rules.
One thing above all others: a third-party certificate of analysis whose batch number matches the vial you were sent. Not a generic PDF for the product line, not an in-house QC sheet, not a purity number printed on the label. Everything else — domestic shipping, responsive support, clean packaging — is table stakes that a bad supplier can fake just as easily as a good one.
Usually it means HPLC peak area: the share of UV-absorbing material eluting as the target peak. It says nothing about what the other 1% is, and nothing about whether the main peak is the peptide you ordered — that takes mass spectrometry. A purity figure without an identity method behind it is half a claim. Look for HPLC and MS on the same report.
Substantially, and that gap is the entire reason the research-peptide market exists. A compounding pharmacy or telehealth clinic is selling a prescription drug with clinical oversight, pharmacy overhead, and liability attached. A research supplier is selling a labeled reference compound with none of those things. You are not comparing two prices for the same product.
Chemically they can be identical — same sequence, same molecular weight, sometimes the same contract manufacturer upstream. What differs is everything around the molecule: sterility assurance, endotoxin testing, fill-finish under GMP, batch traceability, and a regulator who will act if a lot fails. Those controls are most of what a prescription costs.
Retatrutide, by a wide margin — a triple GIP/GLP-1/glucagon agonist still in Phase 3 trials with no approval anywhere. Its Phase 2 weight-loss results were the largest reported for any pharmacological agent, which is why demand for it runs far ahead of its evidence base.
